Fabrice André MD, PhD, oncologist based at Gustave Roussy Cancer Cancer, Villejuif, France is talking about the abstract he submitted for ASCO 2020
Title: Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.
DOI: 10.1200/JCO.2020.38.15_suppl.1009 Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 1009-1009.
Prof. Michelino DeLaurentiis, MD, PhD from the National Cancer Institute Fondazione G. Pascale is commenting on his abstract "DeLaurentiis M. et al. Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC). J Clin Oncol 37, 2019 (suppl; abstr 1041)", which was presented at ASCO 2019 in Chicago
Rafael Villanueva, MD from the Institut Català d'Oncologia, Barcelona, Spain is commenting on his abstract that has been presented at ASCO 2019 in Chicago. Hurvitz S.A. Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. J Clin Oncol 37, 2019 (suppl; abstr LBA1008)
